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 Introduction 
 With improvements in breast imaging, mammography, ultra-
sound and minimally invasive interventions, the detection of early 
breast cancer, non-invasive cancers, lesions of uncertain malignant 
potential, and benign lesions has increased. However, with the im-
proved diagnostic capabilities comes a substantial risk of false-posi-
tive benign lesions and vice versa false-negative malignant lesions.
 Whereas ‘Imaging Report and Data System’ (BI-RADS) lesions 
classified in Group 2 as definitely benign in mammography terms re-
quire no further clarification, it is recommended that cases of tumours 
that are classified as BI-RADS Group 3 in mammography terms 
should be subjected to a shorter follow-up interval or biopsy in view of 
their unclear malignant potential  [1] . Benign breast tumours include 
both lesions classified as BI-RADS 2 (such as lipomas) and tumours 
classified as BI-RADS 3 (such as phyllodes tumours)  [2] . A statement 
is provided on the manifestation, imaging, and diagnostic verification 
of isolated benign breast tumours that have a frequent manifestation, 
in addition to general therapy management recommendations.
 Papillomas 
 Papillomas (first described by Warren in 1905  [3] ) are found in 
around 1–3% of all biopsy tissue samples taken from the breast  [4, 
5] ( figs. 1 ,  2 ). The relevance of milk duct papillomas is not to be 
underestimated despite this relatively low incidence, as they are 
deemed to be a risk factor for malignant processes regardless of 
whether it is a solitary or a multiple manifestation. In pathogenetic 
terms, the development of papillomas can be explained by a rever-
sal of the proliferation direction. Whereas a mesenchymal induc-
tion occurs in all hyperplasias, with papillomas, a strong epithelial 
autonomy results in the formation of free epithelial masses that 
then set themselves apart in the mesenchymal proliferation.
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 Summary 
 With improvements in breast imaging, mammography, 
ultrasound and minimally invasive interventions, the de-
tection of early breast cancer, non-invasive cancers, le-
sions of uncertain malignant potential, and benign le-
sions has increased. However, with the improved diag-
nostic capabilities comes a substantial risk of false-posi-
tive benign lesions and vice versa false-negative 
malignant lesions. A statement is provided on the mani-
festation, imaging, and diagnostic verification of isolated 
benign breast tumours that have a frequent manifesta-
tion, in addition to general therapy management recom-
mendations. Histological evaluation of benign breast tu-
mours is the most reliable diagnostic method. According 
to the S3 guideline and information gained from analysis 
of the literature, preference is to be given to core biopsy 
for each type of tumour as the preferred diagnostic 
method. An indication for open biopsy is also to be es-
tablished should the tumour increase in size in the fol-
low-up interval, after recurring discrepancies in the vac-
uum biopsy results, or at the request of the patient. As 
an alternative, minimally invasive procedures such as 
therapeutic vacuum biopsy, cryoablation or high-inten-
sity focused ultrasound are also becoming possible al-
ternatives in definitive surgical management. The newer 
minimally invasive methods show an adequate degree 
of accuracy and hardly any restrictions in terms of post-
interventional cosmetics so that current requirements of 
extensive breast imaging can be thoroughly met. 
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 Terminology 
 The papilloma group comprises  [6] :
 –  intraductal solitary papilloma 
 –  intraductal multiple papilloma 
 –  papillomatosis 
 –  juvenile papillomatosis. 
 The differentiation is made on the basis of the intraductal distri-
bution of the papillomas, with solitary papillomas finding their gen-
esis in the large, segmental, and subsegmental efferent ducts and 
multifocal localised papillomas originating from the terminal duct 
lobular units  [7] . Papillomatosis is defined as a minimum of 5 pap-
illomas that are clearly separated from each other within a restricted 
segment of the breast tissue  [8] . Juvenile papillomatosis is a neopla-
sia that effects young females and is characterised by an atypical 
papillary ductal hyperplasia and numerous cystic formations. This 
disease is associated with an increased risk of breast cancer  [9, 10] .
 Clinic 
 Age at Manifestation, Size, and Prevalence 
 Intraductal solitary papillomas have a prevalence of 1.8% of all 
mammary tumours, and the manifestation is typically identifiable 
in perimenopausal females  [11] . As longitudinal-oval tumours, 
they generally have a diameter of under 0.5 cm with a maximum 
length of 4–5 cm  [12] . Multiple intraductal papillomas account for 
around 10% of all intraductal papillomas. Compared to solitary 
papillomas, the manifestation is most likely in younger patients 
and more frequently bilateral. Multiple intraductal papillomas are 
also less likely to cause milk duct secretion. Papillomas frequently 
cause serosanguinous milk duct secretion  [6] and 80–100% of cases 
present with secretion or bleeding from the nipple. In this context, 
secretion is a clinical symptom of solitary central papillomas in 
64–88% of all cases, whereby this is only 25–35% of all cases of 
multiple peripheral papilloma  [13] .
 Non-Invasive Diagnostics 
 Palpation 
 A tumour can be palpated in 11–57% of cases of solitary papil-
loma. The detected mass is normally a widened milk duct in which 
the papilloma is able to extend and cause an obstruction.
 Mammography 
 Intraductal papillomas are not normally detected on mammog-
raphy due to their small size and the typical location in the central 
and more compact regions of the breast. Mammographic images 
related to papillomas include circumscribed retroaleolar nodes that 
have a benign appearance, a solitary retroaleolar widened milk 
duct, and seldom microcalcifications  [14, 15] . Some papillomas can 
cause sclerosis with the result that the subsequent calcification pre-
sents as coarsely flocculated, shell-shaped, or punctiform intra-
ductal calcifications that extend along the milk duct ( fig. 2 ).
 Ultrasound 
 Intraductal papillary neoplasias show different ultrasound pres-
entations depending on their macroscopic appearance. A charac-
teristic feature of papilloma is however a widened milk duct with 
an intraductal round focus or a cyst with an intracystic solid struc-
ture  [16] ( fig. 2 ). According to Han et al.  [17] , intraductal neopla-
 1  2 
 Fig. 1. Intraductal papilloma – galactography. 
 Fig. 2. Sonographic presentation of a papilloma. 
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sias are subdivided into 4 categories based on their relationship to 
the milk duct in the ultrasound examination:
 –  Type 1: intraluminal mass 
 –  Type 2: extraductal mass 
 –  Type 3: simple solid mass 
 –  Type 4: a combination ( fig. 2 ). 
 The use of sonographic elastography in combination with con-
ventional ultrasound can improve specificity when it comes to dif-
ferentiating between benign or atypical or malignant papillary 
breast lesions  [18] .
 MRI 
 Intraductal papillomas can present differently on magnetic res-
onance imaging (MRI) examination. Findings include concealed 
formations, small luminal structures, or irregular fast growing le-
sions that cannot be differentiated from invasive malignomas. 
High costs, limited clinical experience, and suboptimal specificity 
restrict the use of MRI in this context  [19–21] .
 Minimally Invasive Diagnostics 
 Based on minimally invasive biopsy, intraductal papillomas are 
classified as B3 lesions in histopathological terms (lesions of un-
clear biological potential)  [22–26] .
 CB 
 Core biopsy (CB) has restrictions similar to those of fine needle 
aspiration cytology (FNAC). There is therefore a general consensus 
with regard to surgical excision being required for papillomas with 
atypical features verified by CB  [27–32] .
 VAB 
 Should intraductal papillomas be detectable on mammography 
and/or ultrasound, a vacuum biopsy (VAB) can be used for both 
diagnostic and therapeutic purposes. This minimally invasive 
method provides secure and accurate tissue analysis and, with a 
high degree of possibility, can remedy symptoms in patients suffer-
ing from nipple discharge  [33] .
 Ductoscopy 
 Ductoscopy is an endoscopic technique to examined and evalu-
ated the interior of pathologically secreting milk ducts [34] . The 
ductoscope can at the same time be used for insufflation, duct lav-
age, or therapeutic interventions  [35] . The use of cytology brushes, 
small baskets, or microbiopsy forceps ensures targeted sampling. 
In ductoscopic terms, normal milk duct epithelium is of a pale yel-
low to pink colour and can have annular folds on the duct wall. 
Ductoscopy has the advantage that an exact localisation of the 
pathological finding is possible, ductal lavage can be conducted 
under direct observation, and intraoperative control is also possi-
ble, especially where there is a manifestation of lesions deep within 
the milk duct system  [36] . However, this method only plays a re-
stricted role as it does not provide access to the terminal duct lobu-
lar units that are often the origin of malignant lesions. The ducto-
scopic appearance of intraductal papillomas can range from red to 
yellow to ashen  [37] . Papillomas can extend into the lumen of the 
milk duct as a polypoid mass where they present as solitary or mul-
tiple lesions – a benign mammary tumour in a single milk duct sys-
tem. In rare cases, papillary lesions can occur in different milk duct 
systems, both unilateral and bilateral  [37] .
 Therapy 
 The decision concerning a suitable therapy for intraductal papil-
loma can be challenging due to the difficult differentiation between 
intraductal papilloma and carcinoma. Surgical excision is generally 
recommended in patients with peripheral multiple intraductal lesions 
and atypical papillomas that are diagnosed based on intraductal 
breast biopsy  [38] . Younger patients with nipple discharge from only 
1 milk duct can be successfully treated with a minimal surgical inter-
vention in the form of a microreductomy. In older patients, a radical 
milk duct excision can be of benefit even if the secretion originates 
from only 1 milk duct. This gives the opportunity to avoid discharge 
from other milk ducts and obtain a complete histology.
 In keeping with the recommendations made by the Arbeitsge-
meinschaft Gynäkologische Onkologie e.V. (AGO Breast Commit-
tee, 2018  [38] ), no additional measures need to be adopted if papil-
lomas are verified by CB or VAB findings that are not atypical, 
provided the biopsy material is representative (100 mm 2 ) and find-
ings are consistent. No data currently exists regarding the proce-
dure to be adopted in cases where there is evidence of papilloma in 
the edges of the resected tissue  [39] .
 Prognosis 
 The risk of an invasive carcinoma developing in the future in pa-
tients with intraductal papilloma (atypical or not) should be evalu-
ated based on the surrounding breast tissue. A benign solitary pap-
illoma without any changes to the surrounding breast tissue indi-
cates only a slightly increased risk of invasive mammary carcinoma 
developing in the future  [38, 39] . The relative risk posed by periph-
eral papillomas can be higher than with central papillomas. Carci-
noma risk is based on the ductal and atypical hyperplasias that ren-
der the development of carcinoma in the terminal duct lobular 
units probable in 12% of cases. Recurrences occur in 23% of cases. 
Papillomas indicate an increased risk of formation of an ipsilateral 
carcinoma. The percentage rates for atypical papillomas are be-
tween 4.6 and 13%. Juvenile papillomatosis appears to be associated 
with an increased risk of breast cancer simultaneously or in the fu-
ture  [40] . No data currently exists regarding the therapeutic proce-
dure in cases where there is evidence of papilloma in the edges of 
the resected tissue. Excision should be carried out in the case of ju-
venile papillomatosis. Close monitoring does not suffice  [41] .
 Mixed Fibroepithelial Tumours 
 Fibroadenomas 
 Fibroadenomas are benign biphasic tumours that originate 
from the terminal duct lobar units as localised tumours and display 
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proliferation of the epithelial and fibrous tissue components ( figs. 
3 ,  4 )  [42, 43] .
 Pathogenesis 
 It is assumed that fibroadenomas are the result of abnormal 
proliferation and involution of the breast tissue due to hormonal 
influences and that they do not present a ‘real’ neoplasia  [44] .
 Terminology 
 Fibroadenomas are subdivided into  [45] :
 –  adult fibroadenomas that typically manifest in young females 
 –  juvenile fibroadenomas that exist during puberty and in adoles-
cents. 
 Clinic 
 Age at Manifestation, Size, and Prevalence 
 After carcinomas, fibroadenomas are the second most-prevalent 
neoplasia of the female breast and the most prevalent tumour in 
females aged under 30  [46] . Their prevalence is reduced to a great 
extent in the postmenopausal period. The average size is between 1 
and 3 cm  [45] .
 Non-Invasive Diagnostics 
 Palpation 
 Fibroadenomas present as painless, solitary, solid, smoothly de-
marcated, slow-growing, and movable nodes.
 Mammography 
 Fibroadenomas normally present on mammography as smooth 
circumscribed lesions; however, 25% of tumours can include fea-
tures suspicious for malignancy. Characteristic aspects are com-
plete or almost complete calcification of the fibroadenoma that 
can have a shell-shaped, popcorn-like, bizarre, or bowl-like form. 
In the case of pericanalicular fibroadenomas, the calcifications can 
take a linear, y, or v form. Calcifications in intracanalicular fi-
broadenomas tend to be rather round or fine-punctiform 
 [47–49] .
 Ultrasound 
 The classic fibroadenoma has the following ultrasound charac-
teristics  [50] :
 –  an elliptical or slightly lobulated form 
 –  greater elongation in the transversal and craniocaudal image 
than in the anterior-posterior image 
 –  isoreflective to hyporeflective echotexture when compared 
with fatty tissue 
 –  completely surrounded by a fine echogenous capsule 
 –  normal or accentuated sonic transmission when compared 
with the surrounding tissue 
 –  fine boundary shadows 
 –  unrestricted movement during palpation 
 –  easily compressed. 
 Fig. 3. a, b Fibroadenoma – sonographic findings. 
 Fig. 4. Fibroadenoma – MRI-findings T2-fs sequence; signal intense. 
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 MRI 
 Fibrosed fibroadenomas uptake only a small quantity of con-
trast medium or none at all. If a non-cystic tumour presents with-
out any uptake, a T2-weighted pulse sequence should be performed 
in order to exclude mucinous carcinoma. A fibrous fibroadenoma 
can therefore be assumed should the signal intensity in the T2-
weighted sequence be low. Fibroadenomas with a high water or cell 
content have a considerable mostly slow but sometimes also fast 
uptake of the contrast medium and show a smoothly demarcated, 
oval, and lobulated appearance with low-signal septa. However, pe-
ripheral enhancement does not indicate the existence of a fibroad-
enoma  [49] .
 Minimally Invasive Diagnostics 
 CB 
 In the diagnosis of fibroadenoma, CB has the benefit of being 
able to detect complex changes and epithelial proliferations more 
easily than FNAC  [48, 50, 51] .
 VAB 
 VAB can be a safe and successful alternative when it comes to 
treating fibroadenomas. In addition to the diagnostic benefits, 
VAB has therefore also gained importance as a minimally invasive 
therapeutic method  [52, 53] .
 Therapy 
 It is assumed that fibroadenomas grow over a period of 12 
months, increasing in size by around 2–3 cm before remaining un-
changed for a number of years. It is also assumed that fibroadeno-
mas tend to regress and lose cell mass the older they become  [54] . 
Should a CB examination therefore detect a fibroadenoma, con-
servative management with close ultrasound follow-up after 6, 12, 
and 24 months should be attempted  [55, 56] . An increase in the 
size of the fibroadenoma within this interval or the occurrence of 
symptoms caused by the tumour should serve as an indication for 
excision biopsy. As the post-interventional cosmetic result plays an 
important role with benign breast tumours, tumour extirpation is 
increasingly being carried out using minimally invasive therapeutic 
procedures as described below  [53] .
 VAB 
 VAB is an efficient and cost-saving therapeutic procedure with 
good cosmetic results that is becoming increasingly popular and 
has developed into the standard management method for the 
treatment of benign breast tumours. Disadvantages are the proba-
bility of recurrence and the possibility that the tumour is not fully 
extirpated. Complete excision and maximum cosmetic outcome 
can be achieved with a tumour size of under 3 cm as a standard 
 [57, 58] .
 Cryoablation 
 This is a method that is almost painless and can be used for su-
perficial lesions. It is therefore the preferred option for patients 
wishing to have their fibroadenoma treated without surgical inter-
vention. This therapeutic method is deemed to be an effective and 
safe way of reducing the size and symptoms of the fibroadenoma 
while achieving excellent cosmetic results. When compared with 
VAB, it was not possible to detect any recurrences. The analgesic 
effect of the cold, the procedure-related lack of any changes being 
discernible on mammographic examination conducted at a later 
date, and the positive immunostimulatory effect are all deemed to 
be beneficial  [59–62] .
 High-Intensity Focused Ultrasound 
 High-intensity focused ultrasound (HIFU) is a non-invasive 
method in which a concentrated ultrasound bundle penetrates and 
heats the tissue exerting a regional effect. When compared with 
cryoablation and radiofrequency ablation, this has the advantage 
that the tissue that is to be destroyed is exactly adapted to the form 
of the tumour  [63, 64] . As this is one of the latest therapeutic meth-
ods for the treatment of fibroadenomas, a large number of clinical 
trials are currently being conducted with regard to its effec-
tiveness.
 Prognosis 
 The breast cancer risk in breasts containing or pretreated for fi-
broadenomas is low, even if a slightly increased risk has been ob-
served [65] . Cases where fibroadenomas have transformed into 
malignant phyllodes tumours are described in the literature [66, 
67] . There is an increased risk of malignant degeneration in cases 
with proliferative changes in the breast parenchyma adjacent to the 
fibroadenoma or in females with complex fibroadenomas and a 
positive family history of breast cancer  [68] . The majority of fi-
broadenomas do not recur after complete surgical excision. In 
younger women, there is a tendency to develop 1 or more new le-
sions either at the surgical site or in other parts of the body.
 Phyllodes Tumour 
 Phyllodes tumours (described for the first time by Johannes 
Muller in 1838  [69] ) are rare breast neoplasias that only account 
for 0.3–1% of all mammary tumours  [70, 71] .
 Terminology 
 Due to its cystic components and fleshy appearance, this tu-
mour was originally referred to as ‘cystosarcoma’. However, taking 
into account that these tumours display benign behaviour in the 
majority of the cases, the World Health Organisation recom-
mended the use of the neutral expression ‘phyllodes tumour’  [72] .
 Pathogenesis 
 The pathogenesis of phyllodes tumours is still not clear. In addi-
tion to a de novo genesis in the breast parenchyma, emergence 
from existing fibroadenomas or malignant transformation of a fi-
broadenoma after radiotherapy are also discussed. Growth-stimu-
lating factors of phyllodes tumours include trauma, lactation, preg-
nancy, and elevated oestrogen levels  [73] .
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 Clinic 
 Age at Manifestation, Size, and Frequency 
 In Western countries, phyllodes tumours account for 2.5% of all 
fibroepithelial breast tumours. The prevalence is predominantly in 
middle-aged females (incidence peak between age 40 and 50 years). 
The mean size is 4–5 cm  [74] .
 Microscopy 
 The histological picture of the phyllodes tumour resembles that 
of the intracanalicular fibroadenoma. Longitudinal ductal sections 
are discernible together with a papillary protuberance of the con-
nective tissue, resulting in the tumour having a leaf-like appear-
ance. The existence of epithelial and connective tissue elements is 
necessary in order to establish the diagnosis. The stroma hereby 
represents the neoplastic components and determines the patho-
logical behaviour of the tumour. Only the stroma cells are able to 
metastasise. The histological differentiation between phyllodes tu-
mour and fibroadenoma is based on the proof of the existence of a 
stroma with a greater number of cells and mitotic activity. Phyl-
lodes tumours are classified as benign, borderline, or malignant 
depending on their histological characteristics  [75, 76] .
 Immunohistology 
 Immunohistochemical tests have proven the benefit of CD10 ex-
pression in differentiating between benign and other forms of phyl-
lodes tumour in addition to estimating the manifestation of distant 
metastases in connection with mammary phyllodes tumours  [77] .
 Non-Invasive Diagnostics 
 Palpation 
 Phyllodes tumours normally present as fast-growing but clini-
cally benign tumours and are frequently located in the upper outer 
quadrants with a homogenous distribution in both breasts. The 
skin above larger tumours can show dilated veins and be of a blue 
colour; nipple retraction is rare. Palpable axillary lymphadenopa-
thy can be detected in up to 20% of patients, but this is seldom the 
case with regard to lymph node metastases.
 Mammography 
 On mammography, phyllodes tumours present as smoothly de-
marcated structures with a smooth and partially lobulated edge 
 [78–86] . A radiotranslucent ring that results from the compression 
of the surrounding mammary connective tissue can be discerned 
around the structure  [87] .
 Ultrasound 
 On ultrasound examination, phyllodes tumours present as 
solid, smoothly demarcated, and lobulated space-occupying lesions 
that can include cystic components. However, a reliable differenti-
ation between benign and malignant forms is not possible by ultra-
sound  [88, 89] ( fig. 5 ).
 MRI 
 The existence of a phyllodes tumour is to be assumed if the fol-
lowing are discernible in the MRI evaluation  [90] :
 –  large structure with a smoothly demarcated edge 
 –  heterogeneous appearance in the T2-weighted sequence 
 –  hyperintense spaces in the T2-weighted fat-saturated and STIR 
sequences that are filled with fluid 
 –  rapid contrast medium uptake in dynamic imaging without 
existence of a washout phenomenon 
 Minimally Invasive Diagnostics 
 CB 
 The interdisciplinary S3 Guidelines for the Diagnostic, Therapy 
and Aftercare of a Mammary Carcinoma recommend classification 
as ‘B3’ should the punch or vacuum biopsy provide indications for 
the existence of a phyllodes tumour. In view of the fact that the dif-
ferentiation from fibroadenoma is impossible, the term ‘fibroepi-
thelial tumour’ should be used in order to avoid a false diagnosis 
(and in turn an undervaluation of the phyllodes tumour)  [91, 92] . 
Although tissue biopsy errors can occur with CB, the selective use 
of CB is an attractive option when it comes to improving the pre-
operative diagnosis of phyllodes tumours.
 VAB 
 Only restricted statements on the use of VAB with phyllodes tu-
mours can be found in the current literature. The preoperative di-
agnosis of phyllodes tumours can be improved by a more frequent 
use of VAB and CB  [93] .
 Therapy 
 Local or wide excision is deemed to be the preferred method 
when treating benign phyllodes tumours. Recurrence of borderline 
lesions and malignant phyllodes tumours can be reduced by wide 
excision with tumour-free margins. Diagnostic local excision biop-
sies or tumour enucleations should be followed up with a definitive 
wide excision  [93] . An annual ultrasound postoperative follow-up 
examination is generally recommended due to the risk of 
recurrence.
 Fig. 5. Ultrasound image of a phyllodes tumour in the left breast – sono-
graphic findings. 
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 Prognosis 
 Phyllodes tumours are classified as benign lesions of uncertain 
biological potential (B3)  [22] . Local recurrences have been de-
scribed for both benign and malignant phyllodes tumours. The re-
curring tumour can reflect the histological characteristics of the 
original tumour or a dedifferentiation (in 75% of cases)  [94] . Recur-
rences generally develop within a period of 2 years. Metastases have 
been described to occur in almost all inner organs although the ma-
jority are detected in the lungs and skeletal system. The highest 
mortality rate is found during the first 5 years after diagnosis. The 
frequency of local recurrence and metastasisation correlates with 
the histological degree of the phyllodes tumours (benign, border-
line, malignant). According to published data, the mean value for 
the general local recurrence tendency of phyllodes tumours is 21%, 
with 17, 25, and 27% for benign, borderline, and malignant phyl-
lodes tumours, respectively. Metastasisation is generally detected in 
10% of cases with a distribution rate of 0, 4, and 22% among benign, 
borderline, and malignant forms, respectively. Manifestation of 
local recurrences after surgical excision is heavily dependent on the 
size of the tumour-free margin zones. Thus, it is recommended that 
tumour extirpation should be carried out in healthy tissue with a 
safety margin of 1 cm or preferably even 2 cm  [95–98] .
 Summary 
 Phyllodes tumours are rare breast neoplasias that only account 
for 0.3–1% of all mammary tumours and are mainly occur in mid-
dle-aged females. They are classified as being lesions of uncertain 
biological potential (B3). Up until the late 1970s, mastectomy was 
the standard surgical procedure for all phyllodes tumours regard-
less of size and histological type. However, radical surgery did not 
provide any survival benefits so that conservative surgical methods 
are used nowadays. A simple intracapsular enucleation (referred to 
as ‘enucleation of the phyllodes tumour’) results in high local re-
currence rates regardless of the histological type. Should a diagno-
sis of phyllodes tumour be established preoperatively, wide exci-
sion should be performed with tumour-free margins of at least 
1 cm from the normal breast tissue, especially in the case of border-
line and malignant tumour forms  [98–104] .
 However, should the histological picture of a preoperative bi-
opsy not conform with the diagnostic imaging, it is recommended 
that an open biopsy be initially carried out. It is generally recom-
mended that an annual follow-up with ultrasound examination 
should be carried out  [39] .
 Benign Mesenchymal Tumours 
 Hamartoma 
 Hamartomas (the term was introduced by Arrigoni et al. in 
1971  [105] ) are localised overgrowths of fibrous, epithelial, and 
lipoferous elements that normally have an encapsulated appear-
ance  [106] ( figs. 6 ,  7 ).
 Pathogenesis 
 The genesis of hamartomas is deemed to be a deformity that oc-
curs during embryonic development in the form of inadequate 
germ tissue differentiation  [106, 107] .
 Terminology 
 The histological variants of hamartoma include  [106] :
 –  adenolipoma 
 –  fibrolipoma 
 –  lipofibroadenoma 
 –  cystadenolipoma. 
 Fig. 6. Hamartoma – mammographic findings. 
 Fig. 7. Hamartoma – sonographic findings. 
 6  7 
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 Clinic 
 Age at Manifestation, Size, and Frequency 
 Hamartomas have a predominant manifestation in the peri-
menopausal age group but may occur at any age. They account for 
4.8% of benign breast tumours  [108] . Hamartomas present as 
round or oval lesions and can reach a diameter of up to 20 cm.
 Morphology/Microscopy 
 Hamartomas are encapsulated tumours that can display fibro-
cystic or atrophic changes; there is a frequent occurrence of pseu-
doangiomatous stromal hyperplasia  [108] .
 Non-Invasive Diagnostics 
 Palpation 
 Hamartomas are frequently asymptomatic and are detected on 
mammography as an incidental finding. Very large lesions can 
cause breast deformation.
 Mammography 
 The majority of hamartomas show a characteristic picture in the 
mammographic examination so that mammography is deemed to 
be the preferred diagnostic method. They present as smoothly de-
marcated masses with a different composition of the fat, glandular, 
and connective tissue content in quantitative terms. The manifesta-
tion of the mammographic density varies and depends on the fat/
parenchyma ratio  [109] . The thin pseudocapsule is fully or partially 
discernible ( fig. 6 ).
 Ultrasound 
 Ultrasound should only be used for the diagnosis of hamarto-
mas in conjunction with mammographic findings. Breast hamarto-
mas display a wide range of ultrasound features so that ultrasound 
only plays a minor role in the diagnosis [110] . Frequently, a 
smoothly demarcated, solid, and poorly echogenic structure with 
dorsal sound disappearance is discernible ( fig. 7 ).
 MRI 
 On MRI, hamartomas present as compact fatty tissue with a 
smoothly demarcated, hypointense border and inner heterogenic 
uptake as characteristic for breast hamartoma  [111] .
 Minimally Invasive Diagnostics 
 CB 
 CB is of limited use, especially in cases where clinical and imag-
ing clues do not exist. The existence of connective tissue within the 
lobuli or a connective tissue and fat content in the stroma, whether 
with or without pseudoangiomatous changes, should provide the 
pathologist with grounds for considering the possibility of a 
hamartoma  [111, 112] .
 Therapy 
 Lesions with a characteristic appearance and typical clinical fea-
tures of a classic hamartoma can be subjected to conservative ther-
apy. Should the tumour present atypical characteristics however, 
e.g., an increase in size or specific symptoms, excision or at least a 
biopsy are recommended  [113–115] .
 Prognosis 
 Hamartomas are benign breast lesions but malignant transfor-
mation is possible  [116] . The literature describes in situ ductal car-
cinomas, infiltrating ductal carcinomas, and lobular intraepithelial 
neoplasias in conjunction with hamartomas  [114–117] . Hamarto-
mas do not tend to recur.
 Discussion 
 Histological evaluation is the most certain diagnostic method 
for benign breast tumours. According to the S3 Guideline and in-
formation gained from the literature analysis, preference is to be 
given to high-speed biopsy (i.e., CB) in each tumour entity  [118] . 
FNAC should no longer be used as standard.
 Only a small amount of information or no information at all 
could be found in the literature regarding the use of VAB, espe-
cially for the very rare tumours; hence, the future significance of 
this method in the diagnosis of rare benign tumours remains to be 
seen. In the case of certain tumours such as adenomyoepithelio-
mas, the use of VAB is recommended before CB  [119] . Milk duct 
papillomas play a special role here as not only standard biopsy 
methods are used for diagnosis and possibly therapy but also duc-
toscopy. It can be determined from the literature that intraductal 
papilloma, phyllodes tumour, neurofibroma, and solitary fibrous 
tumour are the most frequently occurring tumours with a tendency 
to transform or metastasise. Whereas there is a trend in the litera-
ture toward surgical therapy of all forms of phyllodes tumour (be-
nign, borderline, or malignant), the literature regarding intraductal 
papillomas continues to point toward a possible follow-up behav-
iour versus operative therapy  [120] . The AGO recommends con-
servative management of solitary papillomas without any atypical 
characteristics (if biopsy is conclusive and conforms with the imag-
ing) and the performance of an open biopsy for atypical 
papillomas.
 With regard to solitary fibrous tumours, operative therapy is the 
preferred method due to the possible malignant potential  [121] .
 A general recommendation for an open biopsy should therefore 
be made in cases of benign solid tumours of the breast with a 
known increased tendency to transform and metastasise or an un-
clear biological behaviour (B3 lesions). This excludes solitary papil-
lomas without atypical characteristics. In the case of all other be-
nign breast tumours, management could be in the form of a con-
servative procedure with annual ultrasound follow-up examina-
tions after a clinical examination, use of corresponding imaging 
procedures, and last but not least the performance of a punch bi-
opsy to verify the diagnosis. The indication for an open biopsy is 
also to be established should the tumour increase in size in the fol-
low-up interval, after recurring discrepancies in the punch or vac-
uum biopsy results, or at the request of the patient. As an alterna-
tive, minimally invasive procedures such as therapeutic VAB, cry-
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oablation, or HIFU are also becoming possible alternatives in the 
definitive surgical management.
 The newer minimally invasive methods show an adequate de-
gree of accuracy and hardly any restrictions in terms of post-inter-
ventional cosmetics, so that current requirements of extensive 
breast imaging can be thoroughly met.
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